Research programme: HDL cholesterol therapies - Pfizer/Xenon
Alternative Names: HDL cholesterol therapies research programme - Pfizer/XenonLatest Information Update: 05 Jul 2004
At a glance
- Originator Xenon Pharmaceuticals
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Low HDL cholesterol
Most Recent Events
- 29 Jun 2004 Xenon Genetics is now called Xenon Pharmaceuticals
- 30 May 2003 Discontinued - Preclinical for Low HDL cholesterol in Canada (unspecified route)
- 01 Jul 2002 A preclinical study has been added to the pharmacodynamics section